We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

45 hedge funds and large institutions have $137M invested in CERo Therapeutics in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 4

75% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 4

32% more capital invested

Capital invested by funds: $104M → $137M (+$33M)

25% more funds holding

Funds holding: 36 → 45 (+9)

0.01% more ownership

Funds ownership: 0.03% → 0.04% (+0.01%)

Holders
45
Holders Change
+9
Holders Change %
+25%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
7
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$5.97M
2
HIM
HGC Investment Management
Ontario, Canada
+$4.97M
3
LA
Linden Advisors
New York
+$4.97M
4
MI
MMCAP International
Cayman Islands
+$4.97M
5
CCM
Context Capital Management
California
+$3.98M

Top Sellers

Rank Fund Capital Flow
1
UOC
UBS O'Connor
Illinois
-$2.04M
2
OCM
Oaktree Capital Management
California
-$1.98M
3
CL
CSS LLC
Illinois
-$418K
4
TI
Telemetry Investments
New York
-$304K
5
PCM
Pinz Capital Management
New York
-$72K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Wolverine Asset Management
Illinois
$1.55M -$59.7K -3 -4%
PMAM
27
Picton Mahoney Asset Management
Ontario, Canada
$1.5M +$1.49M +75 New
BI
28
Bulldog Investors
New Jersey
$1.09M +$1.09M +55 New
Barclays
29
Barclays
United Kingdom
$1.06M +$1.05M +53 New
TCM
30
Tenor Capital Management
New York
$1M – – –
SCC
31
Spring Creek Capital
Kansas
$1M – – –
SSA
32
Schonfeld Strategic Advisors
New York
$900K – – –
RCM
33
Rivernorth Capital Management
Florida
$500K – – –
WA
34
Whitebox Advisors
Minnesota
$500K – – –
DFCM
35
Dark Forest Capital Management
Puerto Rico
$320K +$119K +6 +60%
LCM
36
Lynwood Capital Management
Ontario, Canada
$296K +$298K +15 New
SC
37
Sculptor Capital
New York
$276K +$279K +14 New
DCM
38
Dupont Capital Management
Delaware
$250K – – –
WP
39
Woodline Partners
California
$250K – – –
SV
40
Starboard Value
New York
$213K -$19.9K -1 -8%
OMC
41
Old Mission Capital
Illinois
$152K +$159K +8 New
HF
42
HRT Financial
New York
$136K – – –
DAM
43
Deltec Asset Management
New York
$100K – – –
SCM
44
Segantii Capital Management
Hong Kong
$100K – – –
AA
45
Ancora Advisors
Ohio
$50K +$59.7K +3 New
UOC
46
UBS O'Connor
Illinois
– -$2.04M -103 Closed
OCM
47
Oaktree Capital Management
California
– -$1.98M -100 Closed
TI
48
Telemetry Investments
New York
– -$304K -15 Closed
PCM
49
Pinz Capital Management
New York
– -$72K -4 Closed
1
2

CERO Hedge Fund Activity: Q1 2022 in Review

45 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2022, worth a combined $137M — up 32% from $104M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new CERO positions and 4 closed out — a net gain of 9 holders — while 7 added to existing stakes and 4 trimmed.

The largest buyer was Periscope Capital, opening a new position worth an estimated $5.97M. The largest seller was UBS O'Connor, exiting entirely with an estimated $2.04M sold.

  • 45 institutional investors held CERo Therapeutics (CERO) as of Q1 2022, up from 36 in Q4 2021.
  • Funds reported $137M of CERo Therapeutics stock for Q1 2022, up 32% quarter-over-quarter.
  • 13 funds opened new CERo Therapeutics positions in Q1 2022 and 4 closed out, a net change of +9 holders.
  • The largest CERo Therapeutics buyer in Q1 2022 was Periscope Capital, an estimated $5.97M added.
  • The largest CERo Therapeutics seller in Q1 2022 was UBS O'Connor, an estimated $2.04M sold.

Based on aggregated 13F filings for Q1 2022.